Generate Biomedicines Inc (GENB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||
| Net Income | -61,714 | N/A | -44,314 |
| Depreciation Amortization | 3,127 | N/A | 2,495 |
| Accounts receivable | N/A | N/A | -91 |
| Accounts payable and accrued liabilities | 3,754 | N/A | -597 |
| Other Working Capital | -30,653 | N/A | -17,440 |
| Other Operating Activity | 5,098 | 0 | 6,771 |
| Operating Cash Flow | $-80,388 | $N/A | $-53,176 |
| Cash Flows From Investing Activities | |||
| PPE Investments | 61,219 | N/A | 152,882 |
| Purchase Of Investment | -321,153 | N/A | -77,350 |
| Investing Cash Flow | $-259,934 | $N/A | $75,532 |
| Cash Flows From Financing Activities | |||
| Debt Repayment | -1,115 | N/A | -2,646 |
| Common Stock Issued | 372,506 | N/A | 22,456 |
| Other Financing Activity | 7,500 | 0 | 750 |
| Financing Cash Flow | $378,891 | $N/A | $20,560 |
| Beginning Cash Position | 126,038 | N/A | 181,831 |
| End Cash Position | 164,607 | N/A | 224,747 |
| Net Cash Flow | $38,569 | $N/A | $42,916 |
| Free Cash Flow | |||
| Operating Cash Flow | -80,388 | N/A | -53,176 |
| Capital Expenditure | -3,781 | N/A | -751 |
| Free Cash Flow | -84,169 | 0 | -53,927 |